MasterCard Incorporated (MA)
MasterCard Incorporated (MA) announced this morning that its first-quarter profit climbed 24% to $455 million, or $3.46 per share, while revenue increased to $1.3 billion. The results surpassed analysts' consensus expectations, which called for a profit of $3.14 per share on $1.27 billion in revenue.
YRC Worldwide Inc. (YRCW)
YRC Worldwide Inc. (YRCW) said today that its first-quarter loss expanded to $274.1 million, or 53 cents per share, from last year's deficit of $273.8 million, or $4.61 per share. Revenue for the period slipped 29% to $1.06 billion. Analysts were looking for a slimmer per-share loss of 48 cents on a more robust $1.11 billion in revenue.
Continental Airlines, Inc. (CAL)
Continental Airlines, Inc. (CAL) said last night that volcanic ash over Europe led to the cancellation of 403 trans-Atlantic flights, and cut capacity by roughly 275 million available seat miles. Overall, the impact of the volcanic ash reduced CAL's monthly consolidated passenger revenue by about $24 million for April.
Overstock.com, Inc. (OSTK)
Online retailer Overstock.com reported a first-quarter profit Tuesday, helped by a steep revenue increase. Analysts had expected a quarterly loss and shares jumped with the news. Shares surged $3.82, or 19 percent, to $23.55, after earlier reaching a nearly two-year high of $26.50. The stock had traded between $10.04 and $21.76 over the past year.
Quarterly profit totaled $3.7 million, or 16 cents per share, compared with a loss of nearly $4 million, or 17 cents per share in the previous year's first quarter.
Analysts polled by Thomson Reuters, on average, predicted a loss of 7 cents per share.
Revenue rose 42 percent to $264.3 million from $185.7 million a year ago.
Sales and marketing expenses rose 5 percent to $14.3 million but fell as a percentage of revenue.
Impax Laboratories, Inc. (IPXL)
Impax Laboratories Inc's (IPXL) quarterly profit handily beat market estimates, helped by higher sales in its generic drugs division and a new drug launch.
The company said its recently launched generic urinary drug added $176.2 million to its total revenue and $167.9 million to its gross profit.
Impax got U.S. marketing approval for a copycat version of Astellas Pharma's (4503.T) Flomax in March.
Net income for the first quarter was $131.5 million, or $2.06 a share, compared with $2.2 million, or 4 cents a share, in the prior-year quarter.
Revenue for the quarter increased more than four-fold to $323.3 million.
Analysts on average were expecting the company to earn 51 cents a share, excluding items, on revenue of $163.4 million, according to Thomson Reuters I/B/E/S.
VIVUS, Inc. (VVUS)
Drug developer Vivus Inc. said Monday its first-quarter loss widened on a decline in revenue following the completion of a deferred revenue deal for the drug Evamist.
Vivus lost $18.8 million, or 23 cents per share, compared with a loss of $6.8 million, or 10 cents per share, during the same period a year prior. Revenue plunged to $1.7 million from $22.2 million.
The company had been receiving deferred revenue from the sale of the spray-on hot flash treatment Evamist in 2008, but the deal ended in May 2009.
Analysts polled by Thomson Reuters expected a loss of 26 cents per share on revenue of $1.8 million.
Force Protection (FRPT)
Force Protection (FRPT) is sitting on a loss of about 5% ahead of tonight's earnings report -- and despite today's news of a substantial Cougar order from the U.S. Marine Corps. Analysts are expecting FRPT to report a first-quarter profit of 7 cents per share, down from 11 cents per share in the year-ago quarter.
Take control of your future prosperity the Easy way. Become a member of Stock Options Made Easy today!